Intravenous fluid exemption: clarificatory amendment cannot be read narrowly to exclude injectable electrolyte products.

An exemption entry for intravenous fluids was treated as clarificatory rather than substantively narrowed by the 2001 amendment, so no restrictive condition of exclusive use for sugar, electrolyte or fluid replenishment was read into it. Technical material showed that Calcium Borogluconate Injection and Calcium Magnesium Borogluconate Injection could be administered intravenously and functioned as electrolyte sources. The absence of a single-dose character did not defeat eligibility, and earlier Tribunal reasoning against a narrow construction was followed. Acceptance of the products for licensing purposes without any manufacturing change also supported the view that the Revenue's objection could not be sustained.

---

---

Issues: Whether Calcium Borogluconate Injection and Calcium Magnesium Borogluconate Injection were eligible for exemption as intravenous fluids under the relevant exemption notifications, and whether the amended description in the notification could be construed restrictively.

Analysis: The exemption entries for intravenous fluids were treated as continuing in substance after the 2001 amendment because the budget notes described the change as clarificatory. The products were supported by technical material showing that they could be administered intravenously and were regarded as sources of electrolyte. The absence of a single-dose character did not disqualify them, and the earlier Tribunal view was applied to reject a narrow reading that would confine exemption only to products used exclusively for sugar, electrolyte, or fluid replenishment. The fact that the same products had also been accepted for licensing purposes without change in manufacture reinforced the view that the Revenue's objection could not be sustained.

Conclusion: The products were held to be eligible for exemption, and the assessee succeeded.

Final Conclusion: The exemption benefit was upheld for the products in dispute, with consequential relief following, and the Revenue's challenge failed.

Ratio Decidendi: Where an exemption entry for intravenous fluids is clarified rather than substantively narrowed, it must be construed without adding a restrictive condition of exclusive use for sugar, electrolyte, or fluid replenishment, and products shown to be administered intravenously may qualify for the exemption.

---